uniQure IP BV – CA2921594A1 AAV Vector Patent Application Refused by CIPO
uniQure IP BV sought Canadian patent protection for AAV vectors with improved rep coding sequences for production in insect cells. The Commissioner of Patents refused application CA2921594A1, finding all 15 claims failed on double-patenting grounds relative to parent patent CA 2,655,957, with two claims additionally held indefinite.
CIPO refuses uniQure AAV vector divisional on double-patenting and indefiniteness
uniQure IP BV, represented by Gowling WLG (Canada) LLP, prosecuted Canadian patent application CA2921594A1 covering AAV vectors with improved rep coding sequences for production in insect cells. The proceeding was heard before the Patent Appeal Board and decided by the Commissioner of Patents, with the decision issued on 19 October 2023. The application is a divisional of parent patent CA 2,655,957.
The Commissioner concurred with the Patent Appeal Board's recommendation to refuse the application. The recorded basis of termination is 'Unpatentable.' The Commissioner's decision identifies three grounds: claims 1–15 do not define an 'other' invention relative to the parent patent contrary to s. 36(2) of the Patent Act; claims 1–15 are not patentably distinct from the parent's claims under the doctrine of obviousness double-patenting; and claims 4 and 8 are indefinite contrary to s. 27(4) of the Patent Act.
The refusal forecloses Canadian patent grant for this application in its current form. The specific prosecution history and claim amendments considered by the Board are not fully reproduced in the available record. uniQure retains a six-month window under s. 41 of the Patent Act to appeal the Commissioner's decision to the Federal Court of Canada; whether an appeal will be pursued is not disclosed in the available record.
See Complete Case & Patent Analysis →Filing to Unpatentable in 0 days
Decision closed 19 October 2023
CA2921594A1 — AAV vectors with improved rep coding sequences for insect cells
Any company developing or commercialising insect-cell-based AAV vector manufacturing in Canada — including CDMOs, gene therapy developers, and academic spin-outs — should assess freedom to operate against uniQure's granted parent patent CA 2,655,957. Although CA2921594A1 has been refused, the parent remains in force and its claims define the live exclusivity boundary. The refused application's claims also reveal the scope uniQure sought to protect, which is instructive for mapping design-around options.
Official order — verbatim text
The Commissioner's decision expressly adopts the Patent Appeal Board's recommendation in full, refusing the application on three independently sufficient grounds: double-patenting relative to CA 2,655,957 under both s. 36(2) and the obviousness doctrine, and indefiniteness of claims 4 and 8 under s. 27(4). The decision preserves uniQure's statutory right to appeal to the Federal Court of Canada within six months; the available record does not indicate whether that right has been or will be exercised.
Commissioner's refusal: what the three grounds mean for uniQure
Obviousness double-patenting bars divisional claims
Under Canadian patent law, a divisional application must claim an 'other' invention relative to its parent (s. 36(2)) and must be patentably distinct. The Commissioner found claims 1–15 of CA2921594A1 failed both tests against parent CA 2,655,957: they neither define a separate invention nor are they non-obvious variants of the parent's claims. This doctrine prevents applicants from extending patent term by re-claiming materially identical subject matter in a child application.
Double-patenting / s. 36(2)No Canadian patent granted; appeal right preserved
The refusal means uniQure IP BV does not obtain patent protection in Canada for the rep coding sequence improvements claimed in CA2921594A1 in their current form. Any commercial exclusivity for this specific formulation in Canada must rely on the parent patent CA 2,655,957 or other granted rights. The applicant has six months from the decision date (19 October 2023) to appeal to the Federal Court of Canada under s. 41 of the Patent Act. The specific terms of any appeal strategy are not disclosed in the available record.
Refusal — appeal option openClaims 4 and 8 held indefinite under s. 27(4)
Independent of the double-patenting objection, the Commissioner found claims 4 and 8 indefinite contrary to s. 27(4) of the Patent Act, which requires claims to distinctly and explicitly define the subject matter of the invention. An indefiniteness finding means the claim boundaries are insufficiently clear to be enforceable. This ground would survive even if the double-patenting objection were overcome on appeal, meaning those claims would require redrafting to be allowable.
Indefiniteness / s. 27(4)AAV insect-cell production IP in Canada remains anchored to parent patent
For competitors and licensees operating in the AAV gene therapy manufacturing space in Canada, this refusal suggests that the scope of uniQure's Canadian protection for rep coding sequence innovations is currently limited to what is granted under parent CA 2,655,957. Companies developing insect-cell-based AAV production platforms should monitor any Federal Court appeal and track the parent patent's claims when assessing freedom to operate in Canada.
AAV manufacturing IP landscapeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | uniQure IP BV | Individual | /Search in Eureka ↗ |
| Defendant | Defendant | Individual | /Search in Eureka ↗ |
| Plaintiff law firm | Gowling WLG (Canada) LLP | Law Firm | Representing uniQure IP BVSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | CIPOSearch in Eureka ↗ |
R&D signals in the AAV gene therapy manufacturing space
Forward-looking patent and R&D intelligence derived from uniQure's CA2921594A1 proceeding and the broader AAV insect-cell production landscape.
uniQure's AAV manufacturing patent portfolio beyond CA2921594A1
uniQure IP BV holds a portfolio of AAV vector and manufacturing patents anchored by parent CA 2,655,957. The refusal of CA2921594A1 suggests the company has pursued layered divisional protection for its insect-cell rep sequence innovations. Mapping uniQure's full Canadian and international filing activity reveals the breadth of exclusivity surrounding its baculovirus-AAV production platform.
uniQure AAV portfolioFiling trends in insect-cell AAV production technology
The baculovirus insect-cell expression system for AAV manufacturing is an active area of patent filing globally, driven by demand for scalable gene therapy production. Tracking filing trends around rep protein optimisation, baculovirus construct design, and insect-cell culture conditions reveals where R&D investment is concentrating and which players are building blocking positions.
Insect-cell AAV filing trendsCompetitor patent activity in AAV insect-cell manufacturing
Beyond uniQure, several gene therapy developers and CDMOs hold patents on insect-cell AAV production methods. Identifying competitor filings in rep sequence engineering, capsid production in Sf9 cells, and baculovirus vector design helps R&D teams anticipate freedom-to-operate constraints and potential partnership or licensing opportunities in this manufacturing niche.
AAV manufacturing competitorsAdjacent white space: AAV rep sequence engineering for novel cell systems
The refused claims focused on insect-cell rep coding sequence improvements. Adjacent white space exists in rep sequence optimisation for alternative expression systems — mammalian HEK293, yeast, and cell-free platforms — as well as novel codon-optimisation strategies not covered by uniQure's parent patent. These areas may represent lower IP-density opportunities for R&D differentiation.
AAV rep engineering white spaceSimilar CIPO patent refusals in AAV gene therapy and biologics
Explore comparable CIPO Patent Appeal Board decisions involving AAV vectors, gene therapy manufacturing patents, and Canadian double-patenting doctrine in the biotechnology sector.
What this case signals for the AAV gene therapy IP landscape
The CIPO refusal of CA2921594A1 highlights prosecution risk in Canadian divisional strategy for gene therapy vector IP.
Canadian divisional strategy for AAV vectors faces double-patenting scrutiny
The refusal confirms that CIPO will rigorously apply obviousness double-patenting to divisional AAV vector applications. Gene therapy IP teams filing divisionals off foundational vector patents in Canada should ensure claims are patentably distinct — not merely reformulated variants of parent claims — before prosecution advances to the Patent Appeal Board.
Indefinite claims in technical biotech applications carry compounding risk
Claims 4 and 8 were rejected on indefiniteness in addition to double-patenting. In complex biotechnology applications involving coding sequences and production systems, claim drafting precision is critical. An indefiniteness finding survives a successful double-patenting appeal, meaning applicants must address both grounds independently to secure grant.
BV v Defendant — key questions answered
The Commissioner of Patents refused CA2921594A1 on three grounds: claims 1–15 did not define an 'other' invention relative to parent patent CA 2,655,957 contrary to s. 36(2) of the Patent Act; claims 1–15 were not patentably distinct from the parent under the doctrine of obviousness double-patenting; and claims 4 and 8 were indefinite contrary to s. 27(4) of the Patent Act. The decision was issued on 19 October 2023.
Obviousness double-patenting is a Canadian patent law doctrine that prevents an applicant from obtaining a second patent on claims that are not patentably distinct from an earlier patent's claims — even if the claims are not identical. The Commissioner found that the claims of CA2921594A1 were obvious variants of the claims already granted in parent patent CA 2,655,957, making separate patent protection impermissible.
Yes. Under s. 41 of the Patent Act, the applicant has six months from the Commissioner's decision date of 19 October 2023 to appeal to the Federal Court of Canada. Whether uniQure has filed or intends to file such an appeal is not disclosed in the available record.
The refusal means uniQure's Canadian exclusivity for improved rep coding sequence technology in insect-cell AAV production currently rests on parent patent CA 2,655,957 rather than this divisional. Competitors should conduct a freedom-to-operate analysis against the parent patent's granted claims. If a Federal Court appeal results in reinstatement of CA2921594A1 claims, the exclusivity landscape could change.
Under s. 27(4) of the Canadian Patent Act, claims must distinctly and explicitly define the subject matter of the invention. The Commissioner found claims 4 and 8 of CA2921594A1 failed this standard, rendering them indefinite. This is a ground independent of double-patenting: even if the double-patenting objection were overcome on appeal, claims 4 and 8 would require redrafting to satisfy s. 27(4).
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.